Clinical trials: Neurodegenerative Disorders
FAP, Familial Amyloid Polyneuropathy
Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)
This study evaluates the safety and tolerability of extended dosing with IONIS-TTR Rx in patients with Familial Amyloid Polyneuropathy.
- Conditions
- FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin
- Trial name
- NCT02175004
- Testing
- Inotersen
- Where
- 22 sites in United States, Argentina and 7 more
- Volunteers
- 135 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Parkinson's Disease
Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System
AIM: To validate the tracer [11C]donepezil for use in the parasympathetic nervous system. MATERIALS AND METHODS: The Investigators will include 7 healthy males aged 45-75 in our study.
- Trial name
- NCT01877538
- Testing
- [11C]donepezil PET
- Where
- Denmark
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Per Borghammer
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This was a multi-center, open-label, Phase Ib dose escalation /Phase II study in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) patients considered to be resistant, ineligible or intolerant to…
- Trial name
- NCT01602315
- Testing
- BYL719 as film-coated (FC) whole tablets, BYL719 as dispersible tablets (DT), cetuximab
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 179 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources
The purpose of this study was to evaluate the use of resources during titration of Duodopa at home.
- Trial name
- NCT01956032
- Volunteers
- 15 people
- Sponsor
- AbbVie
Alzheimer's Disease and Related Dementias
Smart Lighting for Nursing Home Residents With Dementia
This proposed study seeks to develop a smart ambient bright light (SABL) intervention to provide auto-controlled, consistent indoor lighting that incorporates natural daylight.
- Trial name
- NCT05825404
- Testing
- Smart Ambient Bright Light (SABL), Control
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Penn State University
Parkinson Disease
A Pilot Study of Terazosin for Parkinson's Disease
The TZ-PD trial will be a 1:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and tolerability of terazosin for the treatment of PD.
- Trial name
- TZ-PD (NCT03905811)
- Testing
- Terazosin 5 MG
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jordan Schultz
Parkinson Disease, Parkinsons Disease With Dementia
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder causing motor and non-motor symptoms. PD is characterized by death of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta and…
- Trial name
- PD Nilotinib (NCT02954978)
- Testing
- Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Georgetown University
Caregiver Burden, Alzheimer Disease
Reducing Burden in Care Partners of Community-Dwelling Persons With Dementia and Oropharyngeal Dysphagia
The goal of this clinical trial is to learn if a newly-created website tool, called WeCareToFeedDysphagia, helps to reduce feelings of burden in care partners of patients with Alzheimer's disease and related dementias (AD/ADRD)…
- Conditions
- Caregiver Burden, Alzheimer Disease, Dementia, Oropharyngeal Dysphagia
- Trial name
- NCT06557863
- Testing
- WeCareToFeedDysphagia web tool
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Northwell Health
Mild Cognitive Impairment (MCI)
Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)
This research is being done to find out if daily use of the drug levetiracetam can improve memory function in individuals with memory problems like those associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease…
- Trial name
- NCT01044758
- Testing
- Levetiracetam 62.5mg, Levetiracetam 125mg, Levetiracetam 250mg
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Huntington's Disease
Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease
PRECISION-HD1 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120101 in…
- Trial name
- PRECISION-HD1 (NCT03225833)
- Testing
- WVE-120101
- Where
- 21 sites in Australia, Canada and 5 more
- Volunteers
- 61 people
- Sponsor
- Wave Life Sciences USA, Inc.
Alzheimers Disease
The Feasibility of Florbetapir Quantitation
The overall objective of the study is to assess the feasibility of implementing a quantitative process of florbetapir F 18 scan interpretation.
- Trial name
- NCT01946243
- Testing
- Florbetapir F18
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Avid Radiopharmaceuticals
Healthy Volunteers, Alzheimer Disease
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study.
- Trial name
- NCT02323334
- Testing
- LY3202626, Itraconazole
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Parkinson's
Cognitive Dysfunction In Parkinson's
We hypothesize that reductions in gamma activity are a key mechanism underlying cognitive dysfunction in PD and that interventions to increase gamma activity will improve cognition.
- Trial name
- KL2 (NCT02468804)
- Testing
- rTMS
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Independent Living
Implementation of CAPABLE in the Michigan Medicaid Waiver
Main study: Nearly half of older adults report problems with function, which can lead to difficulty with activities of daily living and nursing home placement.
- Trial name
- NCT03634033
- Testing
- MiCAP with IF (Main Study), MiCAP with IF and EF (Main Study), MiCAP with IF and Caregiver Engagement (Administrative Supplement)
- Where
- 18 sites in United States
- Volunteers
- 7,777 people, healthy volunteers welcome
- Sponsor
- Grand Valley State University
Mild Cognitive Impairment, Alzheimer's Disease
Minocycline in Patients With Alzheimer's Disease
Cognitively normal individuals, patients with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) will undergo clinical screening, neuropsychological tests, blood and urine analyses, quantitative magnetic resonance…
- Trial name
- NCT01463384
- Testing
- Minocycline
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Huntington Medical Research Institutes
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Parkinson's Disease, Idiopathic
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months.
- Trial name
- NCT05357989
- Testing
- buntanetap/posiphen
- Where
- 69 sites in United States, Germany and 4 more
- Volunteers
- 523 people
- Sponsor
- Annovis Bio Inc.
Colorectal Neoplasms
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite…
- Trial name
- RELATIVITY-123 (NCT05328908)
- Testing
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Where
- 139 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Bristol-Myers Squibb
Spinal Muscular Atrophy
A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal…
- Trial name
- NCT02644668
- Testing
- Reldesemtiv 150 mg, Reldesemtiv 450 mg
- Where
- 19 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Cytokinetics
Alzheimer Disease
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are…
- Trial name
- NCT00912288
- Testing
- Dimebon 20 mg po TID
- Where
- 47 sites in United States, Canada and 6 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.